Please login to the form below

Not currently logged in
Email:
Password:

short bowel syndrome

This page shows the latest short bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

Pfizer buys dwarfism drug company Therachon for $810m

Pfizer buys dwarfism drug company Therachon for $810m

Will rival BioMarin pipeline drug. Pfizer is spending $340m to acquire Therachon, a European biotech with a drug in trials for achondroplasia, a form of short-limbed dwarfism. ... Therachon has another asset in development, a GLP-2 analogue called

Latest news

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    The recent EMA approval of the subcutaneous formulation of its Inflammatory Bowel Disease (IBD) drug Entyvio was another milestone, as well as an important boost for patients. ... Projects that address gut inflammation beyond IBD are focused on coeliac

  • A rare talent A rare talent

    This is, he adds, “extremely restrictive”, and he points to Revestive (teduglutide), Shire's treatment for the rare and potentially fatal gastrointestinal disorder short bowel syndrome.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel

  • Pharma deals during January 2015 Pharma deals during January 2015

    Paying $46 per share (a 51% share price premium), this deals brings Gattex (teduglutide) used in the long-term treatment of adults with short bowel syndrome into the Shire portfolio and

  • Pharma deals during March 2013 Pharma deals during March 2013

    NPS Pharmaceuticals acquired back from Takeda the rights outside North America to teduglutide, an orphan drug for adult short bowel syndrome and rPTH 1-84, which is approved for osteoporosis in ... 160. † Takeda Pharmaceuticals/ NPS Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....